A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer. The treatment phase of this study will be comprised of 2 sequential parts: an open label treatment phase and a double-blinded treatment phase.
Pancreatic Cancer
DRUG: Simtuzumab|DRUG: Gemcitabine|DRUG: Placebo to match simtuzumab
Progression free survival, Progression free survival is measured as time from date of randomization to the earliest event time of death regardless of cause or first indication of disease progression., Up to 3 years
Overall survival, Overall survival is measured as time from date of randomization to death regardless of cause., Up to 3 years|Objective response, Objective response is assessed by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 as complete response, partial response, stable disease, or progressive disease., Up to 3 years
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer. The treatment phase of this study will be comprised of 2 sequential parts: an open label treatment phase and a double-blinded treatment phase.